Skip to content
About CombiGene
Project
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Media
Press releases
Interviews and presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
About CombiGene
Project
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Media
Press releases
Interviews and presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
SV
Financial reports
12 May 2022
Interim report January – March 2022 for CombiGene AB (publ)
Read More
27 April 2022
Annual Report 2021
Read More
17 February 2022
Year-end report January-December 2021 CombiGene AB (Publ)
Read More
Search
2021
Edit
12 November 2021
Interim report January – September for CombiGene AB (publ)
20 August 2021
Interim report January – June 2021 for CombiGene AB (publ)
12 May 2021
Interim report January – March 2021 for CombiGene AB (publ)
4 May 2021
Annual Report 2020
2020
Edit
14 December 2020
With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01
4 December 2020
CombiGene’s research is recognized internationally after careful scientific review
2 December 2020
CombiGene’s warrants of series TO4 and TO5 utilized to 98.4 per cent
25 November 2020
CombiGene, together with gene therapy manufacturer Viralgen, has successfully completed the first large-scale production of CG01
24 November 2020
Major shareholders and management demonstrate their faith in CombiGene by participating in the warrants of series TO4 and TO5
23 November 2020
CombiGene signs agreement with British Neurochase for optimized administration of CG01, a gene therapy developed for treatment of focal epilepsy
19 November 2020
CombiGene AB (publ): Nominating committee
18 November 2020
Horizon 2020 continues to invest in CombiGene´s epilepsy project
Visa fler
2019
Edit
21 August 2019
Interim Report January – June 2019 for CombiGene AB (publ)
17 May 2019
Interim Report January-March 2019
14 February 2019
Year-end statement January-December 2018
2018
Edit
It seems we can't find what you're looking for.
2017
Edit
22 December 2017
Another gene therapy product was approved by the FDA
8 November 2017
CombiGene has today launched its new website www.combigene.com
20 October 2017
CombiGene will attend “Advanced Therapies Investor Day” in London
19 October 2017
Gene therapy continues to advance
